Complement Deficiencies (CD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Complement Deficiencies (CD) Market Outlook

Thelansis’s “Complement Deficiencies (CD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Complement Deficiencies (CD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Complement Deficiencies (CD) Overview

Complement Deficiencies (CD) cause susceptibility not only to bacterial infection but also to autoimmune disease. Genetically determined MBL deficiencies are observed in autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Observation of the low concentrations of MBL and other complement proteins (e.g. C1q, C1r, C4) and poor activation of the complement system are also characteristic findings of inactive SLE. Complement activation almost inevitably results in some degree of tissue destruction, as seen in rheumatic diseases such as SLE, RA, vasculitis, and antiphospholipid antibody syndrome. Interest in complement in inflammatory disease has led to the development of pharmacologic complement inhibitors such as eculizumab, a humanized monoclonal anti-C5 antibody approved for paroxysmal nocturnal hemoglobinuria. Inflammatory conditions also result from hereditary or acquired deficiencies of complement regulatory proteins. For example, deficiency of the C1q inhibitor protein leads to undue complement activity under metabolic stress and the development of intermittent and potentially life-threatening angioedema. 

• In the USA the estimated C2 deficiency is the most common complement deficiency with frequency estimates of 0.5 to 1 in 10,000 for homozygous C2-deficient patients. Complement deficiencies cause susceptibility not only to bacterial infection but also to autoimmune disease. Patients with specific complement deficiencies are especially prone to SLE; lupus develops in approximately 90% of C1q-null, 75% of C4-null, and up to 30% of C2-null individuals

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: